Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of KBP-089 in healthy adult men
NL-OMON43278Phase 1Active, not recruiting
- Sponsor
- KeyBioscience AG
- Start
- Oct 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and steatosis comparing KBP-089 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and serious adverse events, Concomitant medication use and 3 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
KBP-089
03
Conditions
type 2 diabetes mellitus (T2DM)obesitysteatosis
Beyond the preview
Go deeper on NL-OMON43278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43278.